This document discusses palliative pain management for cancer patients. It defines different types of pain including nociceptive, neuropathic, visceral, bony, and breakthrough pain. It describes tools for assessing pain intensity including visual analogue scales. It discusses the concept of total pain involving physical, psychological, social, and spiritual suffering. It outlines the World Health Organization pain ladder for treating mild, moderate, and severe cancer pain with non-opioids, weak opioids, and strong opioids. It provides guidance on initiating opioids, formulations, routes of administration, and managing side effects.
Palliative care is an approach to care which improves the quality of life of patients and their families facing the problem associated with life-threatening illness.
Palliative care is an approach to care which improves the quality of life of patients and their families facing the problem associated with life-threatening illness.
CME presentation made on 10th Nov 2012. Discusses a Radiation Oncologist's perspectives of cancer pain management, shortcomings of WHO pain ladder, ASTRO guidelines for metastatic bone pain.
Through palliative care, we change the role of a patient into a whole human being.
Through palliative care, we transform the stages leading to death into times filled with life
Effective pain management in terminally ill requires
Understanding of pain control strategies
Ongoing assessment
Diagnosis of pain
Breakthrough pain relief
Fine adjustment of medications
Opioid rotation
Unresolved psychosocial or spiritual issue can be great impact to pain management
Medication non-adherence is a growing concern, as it is increasingly associated with negative health outcomes and higher cost of care. Tackling the burden of non-adherence requires a collaborative, patient-centric approach that considers individual patient needs and results in intelligent interventions that combine high-tech with high-touch.
CME presentation made on 10th Nov 2012. Discusses a Radiation Oncologist's perspectives of cancer pain management, shortcomings of WHO pain ladder, ASTRO guidelines for metastatic bone pain.
Through palliative care, we change the role of a patient into a whole human being.
Through palliative care, we transform the stages leading to death into times filled with life
Effective pain management in terminally ill requires
Understanding of pain control strategies
Ongoing assessment
Diagnosis of pain
Breakthrough pain relief
Fine adjustment of medications
Opioid rotation
Unresolved psychosocial or spiritual issue can be great impact to pain management
Medication non-adherence is a growing concern, as it is increasingly associated with negative health outcomes and higher cost of care. Tackling the burden of non-adherence requires a collaborative, patient-centric approach that considers individual patient needs and results in intelligent interventions that combine high-tech with high-touch.
Watch the recorded webinar at http://www.mainewellness.org/cannbis_in_cancer_treatment_webinar_recording
From prevention through treatment and remission, cannabis is a powerful tool in the fight against cancer–the government’s National Cancer Institute has even updated its information to reflect the plant’s anti-cancer properties!
Join us and special guest, Molly Stewart, of the Cancer Community Center, for a discussion of the scientifically-proven and real-life benefits of cannabis in cancer treatment, and to learn more about support services and resources for cancer patients and their families.
Translational Medicine: Patterns of Response to Antidepressant Treatment and ...Joanne Luciano
This is a talk I gave at the IEEE Schenectady Section - 17 MAY Membership Meeting.
The mission of my depression research is to help people figure out what they need to help them get out of a depressed state. That is, finding out what is best for them, not what is best for their doctor, friends, therapist, or anyone else. Depression is now a global problem. In the past 15 years it has gotten worse. Depression is complex; it has a wide range of varying symptoms and degrees of intensity. It can be challenging to determine the best course of action, whether medical treatment is necessary, or which of the many treatments (drug and non-drug) is the best match. Many people who are depressed do not get the help they need, and many people receive medications when they are not necessary. My work aims to bring together tools, technology, scientific and medical data and patient experience to help address depression, both personally and globally.
ECO 11: Medicines Optimisation Through Precision - Sir Munir PirmohamedInnovation Agency
Munir Pirmohamed discusses the potential impact of medicines optimisation in terms of ensuring the right patients get the right choice if medicine at the right time. He presents a case history of over prescription and introduces three examples of medicines optimisation through use of genetics, big data, and pharmacogenetics profiling.
Charlie Keller, a primary care physician at Mercy Clinics, Inc. describes Mercy's experience with shared decision making implementation.
This presentation was part of a Shared Decision Making Month webinar -- Shared Decision Making in the Real World: Stories from the Frontline.
this topic explains the nature of pain, signs and symptoms of pain, different types of pain, factors influencing pain, assessment of pain and pharmacological and non pharmacological management of pain.
Pain management: An Interdisciplinary Approach | VITAS HealthcareVITAS Healthcare
Pain management is first and foremost in a hospice patient’s plan of care. Hospice provides comfort and quality of life near the end of life, and hospice providers are experts at managing pain. The goal of this webinar is to help healthcare professionals understand all aspects of a patient’s pain as a symptom near the end of life, and how to utilize an interdisciplinary approach to provide the most effective pain management.
Building on the lecture I gave (and uploaded) "Palliative Care: what every primary care doctor should know" I built this talk. It is geared for 1st year medical students who are learning anatomy, physiology, and perhaps some pharmacology and pathophysiology.
In this talk, I do not explicitly address hospice care - as that was provided in an online chapter for students at UMass. I will later upload another slide set on that topic.
I hope you enjoy it.
FYI- the link to the youtube video: http://www.youtube.com/watch?v=XHtHXGhTIC4
Link to PDF of the slide show: https://files.me.com/s.mak/8fzat6
2. Content
• Pain – definition, assessment
• Nociceptive and Neuropathic Pain
• Types of pain in cancer
• Opioids – principles and WHO ladder
• Opioids – titration, relative potency,
prescribing, formulations, side-effects
• Opioid Induced Neurotoxicity (OIN)
• Adjuvants for types of cancer pain
3. Principles used in symptom control
• What causes the symptom ?
– Physical
– Psycho-social
– Spiritual
• How do we manage it ?
• Treat the treatable
• Symptom control
• Review your
management –
things change!
5. Pain and advanced cancer
• .. are not synonymous
• ¼ of patients do not have pain
• ¾ of patients experience pain at some stage of
their illness
– 1/3 of patients have 1 pain
– 1/3 of patients have 2 pains
– 1/3 of patients have >3 pains
6. Causes of pain in cancer patients
Cancer related …
• Visceral
• Bone
• Soft tissue infiltration
• Nerve compression/infiltration
• Muscle spasm
• Raised intracranial pressure
• Metabolic/ Endocrine
7. Causes of pain in cancer patients
Treatment related …
• Surgery
– Surgical wound – acute / chronic
– Adhesions
• Radiotherapy
– Acute / chronic e.g. mucositis / fibrosis
• Chemotherapy
– Acute / chronic e.g. mucositis / neuropathy
8. Causes of pain in cancer patients
Associated factors …
• Constipation
• Pressure sores
• Bladder spasm
• Joint stiffness
• Post herpetic neuralgia
9. Causes of pain in cancer patients
Concurrent illnesses …
• Low back Pain
• Angina
• Arthritis
• IBS
• Trauma
• Other
11. What is “Total Pain”?
Total
Pain
Physical
Other symptoms
Adverse Rx effects
Insomnia/Chronic fatigue
Psychological
Anger
Disfigurement
Fear of pain/death
Helplessness
Social
Family/Finance worries
Loss of job/income
Loss of role
Abandonment/Isolation
Spiritual
Why me?
Anger at God
What is the point?
Guilt
12.
13. Other cancer problems
• Social circumstances
• Family communication
• Patient coping - denial
• Family coping
• Treatment side-effects
• Disease symptoms - recurrent disease
• Genetics
14. SYMPTOMS IN ADVANCED CANCER
0 10 20 30 40 50 60 70 80 90
Asthenia
Anorexia
Pain
Nausea
Constipation
Sedation/Confusion
Dyspnea
% Patients (n=275)
Ref: Bruera 1992 “Why Do We Care?” Conference; Memorial Sloan-Kettering
15. Pain
• Defined as an unpleasant sensory and emotional
experience associated with actual or potential
tissue damage
• Acute pain is generally sudden in onset,
temporary, and subsides of its own accord or after
successful treatment of the cause
• Chronic pain persists or recurs for prolonged and
often indefinite periods of time
16. Pain Assessment
• Measure pain levels with the patient at regular
intervals.
• Cause of pain should be identified and treated
promptly.
• Patients can describe:
– location of pain
– aggravating or relieving factors
– intensity or severity
– goals for pain control
– duration, and when it occurs
17. Pain Scale
Visual Analog Scale (VAS) 100mm long
Simple Descriptive Pain Intensity Scale
Numeric Rating Scale (NRS)
No
Pain
No Pain
No Pain
Mild
Pain
Moderate
Pain
Severe
Pain
Worst Possible Pain
0 1 2 3 4 5 6 7 8 9 10
Worst Possible Pain
20. Classification of Pain
• Nociceptive pain - tissue damage (two types)
• Somatic
– e.g. metastatic bone pain
• Visceral
– e.g. liver capsule pain
– e.g. colic from malignant bowel obstruction
• Neuropathic - arises from nerve damage
• Central [brain, spinal cord, autonomic]
• Peripheral nerves
– Dysesthetic (burning)
– Lancinating/shooting
– Sensory changes – hyperaesthesia, allodynia, numbness
21. • Somatic Pain
• Arises from bone, muscle, cutaneous and
connective tissue
• Localised
• Typically clinically described as throbbing,
aching or stabbing
• Visceral Pain
• Arises from internal organs
• Generalised / diffuse
• Clinically, typically described as cramping or
gnawing
Nociceptive Pains
23. Types of pain in cancer
• Visceral pain
• Neuropathic pain
• Bony pain
• Referred pain
• Breakthrough pain
24. Visceral Pain
• Results from infiltration , compression,
distension or stretching of thoracic and
abdominal viscera
• Often poorly localised
• Often referred to cutaneous sites
• Can usually be well controlled and
responds well to analgesics
25. Neuropathic pain
• Pain caused by injury to,
or disease of, the PNS or
CNS
• Puzzling & frustrating:
– often seems to have no
cause
– may respond poorly to
treatment
– can last indefinitely
– can escalate over time
– often results in severe
disability
26. Neuropathic pain
• Most distinguishing feature:
anatomical pattern of distribution,
pain follows nerve distribution
• Two broad classifications:
–constant (often described as
burning, throbbing, or stinging)
–intermittent (often described as
sharp, jabbing, or shooting)
• Often worse at night
27. ‘Bony’ pain
• Can be very painful
• Cancer cells multiply
inside the bone and put
pressure on the nerves
• Also causes bones to
crumble – this exposes
the nerves, and leads to
more pain
• Responds well to
analgesics and
radiotherapy
28. Referred pain
• Pain from internal
organs felt at a site
distant from the tissue
damage
e.g. pancreatic cancer
pain is felt in the back
29. Breakthrough pain
• Transient increase in pain over ‘baseline’
• Rapid onset and severe
• Frequent breakthrough pain may indicate
inadequate control of ‘baseline’ pain
30. Dose for breakthrough cancer pain
The breakthrough dose should be equivalent to a
4 hourly dose
• i.e. - 1/6th of total daily opioid dose
• Generally use the same opioid as being used for
regular regimen
33. Increasing ATC Medication – May
Increase Side Effects
Around-the-
clock
Medication
Breakthrough
Pain
Theoretical Model
PainIntensity
Time
34.
35. Commonly used medication in
palliative care patients
• Analgesics
• Antiemetics
• Laxatives
• Antispasmodics
• Anticholinergics
• Anticonvulsants
• Antidepressants
• Corticosteroids
• Antibiotics
• Sedatives
36. Drug complications
• Allergy
• Predicted
pharmacological effects
• Increased drug levels
– Organ failure
– Increasing age
• BNF appendices
– Organ failure
• Liver impairment
• Renal impairment
– Drug interactions
37. Basic Principles of Opioid Analgesia
The right dose of opioid is the one that achieves the
best analgesia with the fewest side effects.
• By the cause of the pain(s)
• By the clock
• By the ladder
• By the mouth
• For breakthrough pain
• For the individual
• Adjuvant therapies as needed
• Prevent side effects
38. Opioid Side Effects
Advise patients
• Constipation
– Co-prescribe laxatives e.g. Senna/Lactulose
• Nausea & vomiting (30%)
– Prophylactic anti-emetics e.g.. Haloperidol/Cyclizine/
Domperidone/Metoclopramide
• Sedation
– Reassure and monitor
– Advise re driving
• Dry mouth
39. Polypharmacy
• Concurrent use of several different medications
• Drug interactions
• Increased cost
• Non compliance
• Adverse effects
• Study GP
– Use >5 medications – increased risk
40. • Polypharmacy & drug interactions
• Cytochrome P450 interactions with inhibition
or induction of drug biotransformation
(‘bullets’ & ‘blanks’)
• Terfenadine/ ketoconazole- cardiac
dysrhythmias by inhibition of terfenadine
metabolism
• Rifampicin / phenytoin increases
phenytoin clearance- reduced effect
41. World Health Organization Pain Ladder
Cancer Pain Management
Increasing Pain
Step 1
Step 2
Step 3
Non-opioid
+/- Adjuvant
Opioid for mild
to moderate pain
+/- Non-opioid
+/- Adjuvant
Opioid for moderate
to severe pain
+/- Non-opioid
+/- Adjuvant
Address psychosocial and spiritual issues; consider adjuvant therapies
Step 4 ?
43. Paracetamol
Active metabolite of phenacetin
Mode of action: Analgesic
Weak prostaglandin inhibitor
Indications: Mild to moderate pain without
inflammation
Adverse effects: Rare at normal dosage
Liver/renal toxicity in overdosage
44. Mode of Action
Produce analgesia through actions at regions in the brain that contain endogenous
opioid peptides
Receptor Subtype
Mu Delta Kappa
Opioid Peptides + +
AGONIST
Codeine
Morphine
PARTIAL AGONIST
Buprenorphine
(+)
+
±
(+)
(+) (+)
45. Prescribing Opioids
• Weak opioids
– Dose often Codeine limited by presence of
paracetamol
– Tramadol
• Strong opioids
– Morphine, oxycodone, diamorphine, fentanyl,
hydromorphone, methadone, buprenorphine
• Do NOT use:
– Pethidine
50. Routes of Opioid Administration
• Preferred route – oral
• When unable to swallow: SC, CSCI, IV, TD
• Seldom used (only in special situations):
– Sub Lingual (breakthrough pain, fentanyl)
– Intraspinal (epidural or intrathecal)
• Do NOT use IM
51. Titrating the Dose of Opioid
Increase the dose by 25-50% if the patient is not
achieving adequate pain control.
Take into account number of breakthrough doses
taken.
52. Opioid Myths
Many patients harbor fears about opioids.
• “It means the end is near”
• “Opioids cause addiction”
• “Opioids will lose their effectiveness over time,
leaving nothing to treat severe pain ‘at the end’”
• “Opioids will make me a zombie or take away my
mental capacity”
• “They will stop my breathing”
• “They will my shorten life”
53. Common Opioid Adverse Effects
Common side effects:
• Constipation (requires ongoing laxatives)
• Nausea
– Usually resolves after a few days
– Metoclopramide or cyclizine in the first few days
• Sleepiness (usually resolves after a few days)
Less common side effects:
• Opioid neurotoxicity
• Sweating, dry mouth, pruritis – very uncommon
(especially with appropriate dosing)
• Respiratory depression
56. Management of Opioid Neurotoxicity
(OIN)
Seek advice from the Specialist Palliative Care
Team
Exclude other causes for symptoms.
The main strategies for treatment of OIN are:
– Hydration
– Opioid dose reduction
– Opioid switching
– Change route of administration
57. Constipation – management
• Pre-empt constipation by putting everyone at risk (e.g.
patients on opioids) on regular aperients
• Treat reversible causes e.g. give analgesia if pain on
defecation, alter diet, ↑ fluid intake
• Treat with regular stool softener (e.g. lactulose) ± regular
bowel stimulant (e.g. senna) or a combination drug (e.g. co-
danthrusate). Titrate dose against response
58. - If that is ineffective consider adding rectal measures.
• if soft stools and lax rectum—try bisacodyl suppositories
(0 must come into direct contact with rectum);
• if hard stools—try glycerol suppositories—insert into the
faeces and allow to dissolve
• - If still not cleared refer to the district nurse for lubricant
± high phosphate (stimulant) enema (usually act in
~20min.)
• - Once cleared leave on a regular aperient with
instructions to ↑ aperients if constipation recurs.
Constipation – management
59.
60. Types of pain in cancer
• Visceral pain
• Neuropathic pain
• Bony pain
• Referred pain
• Breakthrough pain
61. Adjuvants for Visceral Pain
• Liver metastases or malignant bowel
obstruction
– Corticosteroids (Dexamethasone 2-8 mg OD or BD)
– NSAIDs e.g. Diclofenac SR 75mg bd
• Colic
– Hyoscine Butylbromide SC (20mg)
62. Dysaesthetic pain
(burning)
Neuralgic pain
(lancinating)
Opioid and dose titration
(moderate to severe pain)
Gabapentin or Pregabalin or TCA
TCA and Gabapentin or Pregabalin +/- lidocaine patch
Corticosteroid (may be used first line in pain crisis)
NMDA antagonists (ketamine)
Drugs for Neuropathic Pain
63. Adjuvants for Bone Pain [1]
• NSAIDs
– Limited use in severe pain
– Renal and gastro-intestinal side effects
– Limitations of Cox-2 specific NSAIDs recently noted
• Steroids
– Useful in pain crises
• Radiotherapy
– 75% to 85% response rate (decreased pain)
– Few side effects with palliative therapy
– Response within 1 to 2 weeks (maximum response up to 4
weeks later)
– Duration of analgesia is several months
64. Adjuvants for Bone Pain [2]
• Bisphosphonates
– Reduction of skeletal events (good evidence)
– Management of more acute pain with parenteral
infusion (some controversy)
• Surgery
– impending or pathological fracture
66. Pain Management
• Nociceptive Pain
– Somatic: arises from bone, muscle, cutaneous tissue and CT. localised, clinically
presents as throbbing/aching/stabbing pain.
– Visceral: internal organs, generalised diffuse achy pains like period pains
• Neuropathic Pain
– Arises from neural tissue: PNS or CNS
– Can be continuous or spontaneous, descriptions vary from burning to electric
– Associated with allodynia (slightest touch causes pain), hyperalgesia (exaggerated pain
response)
– May be disproportionate to injury (chronic) or indicate neural compression (cancer)
– May respond poorly to treatment
– Can last indefinitely and escalate over time – severe disability
– Distinguishing feature: anatomical pattern of distribution
– Constant or intermittent – burning, throbbing OR sharp stabbing, jabbing
– Often worse at night
– Rx: gabapentin, pregabalin, amytriptyline, paroxetine, opioids help a bit, ketamine
• Visceral Pain
– Arises from internal organs, is generalised or diffuse and poorly localised
– Crampy/colicky pain
– May respond better to anti-cholinergic/anti-spasmodics e.g. buscopan
67. Pain Management
• Referred Pain
– Pain from internal organs felt at a distant site from tissue damage
– E.g. back pain in pancreatic cancer, shoulder tip pain in diaphragm irritation
• “Bony” Pain
– Can be really painful
– Cancer cells multiply inside bones and put pressure on the nerves, they also cause
bone to crumble which exposes the nerves pain
– Responds well to analgesics and radiotherapy
– Pathological fractures and prophylactic stinting
• Breakthrough Pain
– Transient increase in pain over “baseline”
– Rapid onset of severe pain
– May indicate inadequate control of baseline pain if frequently occurring
– Dose = 1/6 of daily opioid dose ( one 4hourly dose)
– Same opioid as baseline medication, faster acting if possible
– Careful of A/Es
– If too much breakthrough being used: review analgesia and change dose
68. Pain Management
• Prescribing Opioids
– Weak: codeine dose often limited by paracetamol. Tramadol used but nauseating and
causes delirium
– Strong: morphine, oxycodone (oxycontin-baseline and oxynorm-breakthrough),
diamorphine, hydromorphone, methadone (good for neuropathic pain but last line),
buprenorphine
– Do NOT use pethidine: useless, causes epileptic fits
– Codeine is metabolised to morphine – 10g codeine = 1g morphine
• E.g. 2 x 8/500 codeine = 16 codeine = 1.6 morphine
69. Pain Management
• Starting Doses
– Morphine: 2.5-5mg q4hr PO
– Oxycodone 1-2mg q4hr PO
– Diamorphine 2.5mg q4hr SC
– Fentanyl transdermal patch for stable pain 12mcg/hr (=45mg oral morphine)
– Add breakthrough dose: 1/6 daily dose
– Smaller doses in renal impairment, old, frail, hepatic failure
– Monitor A/Es for toxicity
– Onset: 15-30min PO, 5-10min SC, 1min IV
– Duration: short acting 3-5 hours (4hrly), long acting 8-12hrs, fentanyl patch 72hrs,
IV/SC 2-4hrs
– Long acting: stable pain
– Short acting: breakthrough, pain crises, opioid naïve pts
– CSCI: continuous sub cutaneous infusion
– Do NOT use IM
– Inadequate pain control: increase dose by 25-50%
– A/Es: constipation (laxatives), nausea, (anti-emetics), sleepiness. OD, sweating, dry
mouth, pruritis, resp depression
70. Pain Management
• Opioid Induced Neurotoxicity
– Presentation: myoclonus, hallucinations (flashes of light), cognitive impairment,
delirium, severe somnolence, dysaethesia, allodynia
– Mechanism: unsure if due to opioid metabolites or opioids themselves
– Increased risk: renal impairment, high dose opioids, infection (natural opioid released
by body)
– RR 8+: watch
– RR<8 – give naloxone slowly. Reverses A/Es as well as pain effects
– Management: hydration, opioid dose reduction, opioid switching, changed route
• Adjuvants for visceral Pain
– Liver mets or malignant bowel obstruction: steroids, NSAIDs
– Colic: hyoscine butylbromide – buscopan 20mg
• Adjuvants for bone pain
– NSAIDs – if not severe, careful with kidneys and liver
– Steroids: good for pain crises. Not long term
– Radiotherapy: 75-85% response rate within 1-2weeks, lasts several months
– Bisphosphonates: reduces skeletal events, helps with pain
– Surgery: stent impending or pathological fracture